Category: Uncategorized

Why Are Colorectal Cancer Patients Getting Younger?

Increasing numbers of younger patients are being diagnosed with late-stage colorectal cancer.

What are the Epidemiological factors behind it, the age groups being affected, symptoms people should be paying attention to, preventative screening options, and where the research is going to try to reverse this alarming trend?

“I know this is an uncomfortable conversation for some, but it’s really important, and if there’s any question about whether polyps were removed and whether they’re the advanced kind or not … take photos to show those to your doctor,” Patel said. “Because patients with a family history of advanced polyps qualify for screening earlier and more frequently.”

https://news.cuanschutz.edu/news-stories/why-are-colorectal-cancer-patients-getting-younger

More than ‘just’ a GP

Research has shown that junior doctors are exposed to significant negative discourse around general practice as a specialty during their hospital-based training. The blaming of GPs for emergency department crowding is almost as inevitable as brand-new Health Ministers blaming consultants for the failings of the entire HSE (brand-new Health Ministers don’t tend to blame GPs for anything; they just forget we exist).

Perhaps we need to change the hashtag to #JustaHuman.

More than ‘just’ a GP

New Approaches to Hereditary Cancer Risk Assessment in Lynch Syndrome and Beyond

Case Conference, during which Matt Yurgelun, MD (@MattYurgelun) from @DanaFarber discusses new approaches to hereditary colorectal cancer risk assessment.

Are physicians losing public trust?

“It’s become clear to me that we as physicians and a healthcare system have lost the trust of the public, and I think it’s time we talk openly about what we as a medical community can do to gain it back.”

What physicians say publicly to and about their patients is important to preserving the public’s need to maintain that trust.

If doctors truly don’t want their patients to seek health information online, they need to do this: create a prescription pad-like  list of credible online health resource links that they will feel comfortable sharing with every patient.

“Patients have every right to be suspicious of a system so dysfunctional as to deny them care in the name of profit. Look at the behavior of drug manufacturers, pharmacy benefit managers, insurance companies, and hospitals — they all prioritize profits over patient care.”

Are physicians losing public trust?

Drug Approval/Reimbursement Process in Ireland

Once a medicine has been approved at a European level, the pharmaceutical company will make separate applications for reimbursement at a national level in different EU or EEA countries. In Ireland these applications are made to the HSE Corporate Pharmaceutical Unit (CPU) who then commission the National Centre for Pharmacoeconomics (NCPE) to carry out an assessment on that medicine.

A full health technology assessment (HTA) is a systematic assessment of the clinical and cost-effectiveness of a medicine. Only a selection of medicines are required to undergo a full HTA as part of the drug reimbursement process. The NCPE full HTA assessment takes approximately 18 weeks to complete, exclusive of the duration the HTA is queried with the Applicant (approximately five weeks as part of the stop/clock process). The full HTA report consists of the following information:

  • Disease background and epidemiology
  • Detailed description of current clinical practice and treatment options
  • Detailed description of the intervention (drug) under assessment
  • Detailed review of the clinical and comparative efficacy of the drug under assessment
  • Detailed review of the safety and comparative safety of the drug under assessment
  • Detailed review of the cost-effectiveness of the drug under assessment
  • Detailed review of the budget impact of the drug under assessment.

The outcome of a full HTA is a recommendation to the HSE on reimbursement. 

I’m confused…

Do public cancer patients have the same chance of living as those with health insurance? It appears you have across all cancers a better, faster access to cutting-edge drugs in the private system compared to the public system

Are pharmaceutical companies making separate applications for reimbursement at a national level in a timely manner? If so why is this?

Is NCPE adhering to its own time frames? If not why?

It appears that up to 40% of the new medicines approved by the EMA are not even assessed by the HSE because its approval system is so protracted it can sometimes take up to three years for the health authority to decide whether to provide the drug free of charge.Is this a process being used to slow down the approval of new drugs to save money?

Who is actually in Charge of spending the Taxpayers money?????

EVERY STORY COUNTS

Especially on World Cancer Day.

Cancer is more than just a medical diagnosis—it’s a deeply personal matter. Behind every diagnosis lies a unique human story – stories of grief, pain, healing, resilience, love and more.

That’s why a people-centred approach to cancer care that fully integrates each individual’s unique needs, with compassion and empathy, leads to the best health outcomes.

Why is it so hard to….TREAT THE PERSON, NOT JUST THE DISEASE.

People living with cancer don’t always feel heard, seen, or understood. They might feel alienated and voiceless at a time when they’re also learning to navigate an unfamiliar and confusing health system, not to mention dealing with the emotional highs and lows of cancer diagnosis, treatment, or recovery.

People-centred cancer care represents an opportunity to refocus, rewire, and rewrite how we think about cancer, to embrace people’s differences, and to make sure that everyone is seen for who they really are and has access to the care they need. 

No other landscape in medicine has changed as drastically as the field of Clinical Genetics – Is Ireland behind the curve?

Advances in technology have been a major driver of the explosion of knowledge in genetics, now allowing us to sequence the entire human genome in a short period of time and at a fraction of the cost of previous years.

This has led to a better understanding of the natural history of cancer, the ability to assess genetic risk for cancer across populations, the development of clinical management strategies to reduce cancer risk, the development of novel therapeutic agents which target genetic alterations, and to improved education of patients and providers about genetic risk.

Hereditary cancer is hard enough to navigate, so we are thankful for patient-friendly information to help inform the decision-making process.

https://www.stjames.ie/cancer/yourtreatmentandcare/servicesandtreatments/cancergeneticsservice/

Genetic testing is a vital tool in enabling individuals to be proactive in their health care to achieve the best possible outcomes.

It’s very important for everyone to understand their cancer risks based on their personal or family history since their personal risk level may necessitate earlier, more frequent, and/or more intensive cancer surveillance.

This is the best way to ensure that you are doing everything you can to prevent cancer or catch it early when treatment has the best outcome.

At present cancer genetics services in Ireland are underdeveloped and underfunded. Only a fraction of staff required are in place. As a result long waiting times, extra cost to the state because cancers are not prevented and discovered at a later stage.

More Evidence that Molecular Residual Disease Monitoring Could Guide Adjuvant Therapy in Colorectal Cancer

Studies have found that the ctDNA blood test can reliably detect “molecular residual disease” (MRD) – essentially, small traces of cancer left after surgery. Patients who test positive for MRD have a higher risk of their cancer returning.

In colorectal cancer, circulating tumour DNA (ctDNA) has become a minimally invasive and dependable prognostic biomarker for identifying post-surgical MRD and assessing the risk of recurrence.

In a recent update from the CIRCULATE-Japan GALAXY observational study, results reinforced previous studies demonstrating that monitoring ctDNA can help detect MRD and assess the risk of recurrence in patients with resectable CRC. 

https://news.cancerconnect.com/colon-cancer/more-evidence-that-molecular-residual-disease-monitoring-could-guide-adjuvant-therapy-in-colorectal-cancer-